Global GAS Vaccine Based On The M-Protein

基于 M 蛋白的全球 GAS 疫苗

• 批准号: 7493529
• 负责人: Michael F Good
• 金额: $ 51.29万
• 依托单位: QUEENSLAND INSTITUTE OF MEDICAL RESEARCH
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-15 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7493529
• 关键词: Acute; Acute Disease; Acute Rheumatic Heart Disease; Adjuvant; Adult; Age; Antibodies; Antibody Formation; Antigens; Australia; Autoimmune Process; Benign; Categories; Child; Class; Clinical; Clinical Trials; Compatible; Control Groups; Country; Cyclic GMP; Data; Developed Countries; Developing Countries; Development; Development, Other; Diphtheria; Disease; Drug Formulations; Effectiveness; Epidemiology; Epitopes; Evaluation; Fiji; Funding; Glomerulonephritis; Goals; Guanosine Monophosphate; HLA-DR2 Antigen; HLA-DR3 Antigen; Human; Immune; Immune response; Immunoglobulin A; Immunoglobulin G; In Vitro; Incidence; Industry; Infectious Skin Diseases; Intellectual scale; Invasive; Licensing; Lipids; Longevity; Marketing; Measures; Mediating; Medical Surveillance; Mind; Modeling; Morbidity - disease rate; Mus; N-terminal; Necrotizing fasciitis; Numbers; Orphan; Pathogenesis; Patients; Peptides; Pharmacologic Substance; Pharyngeal structure; Pharyngitis; Phase; Phase I Clinical Trials; Phase II Clinical Trials; Population; Positioning Attribute; Post-Streptococcal Glomerulonephritis; Prevention; Primary Prevention; Process; Production; Property; Public Health; Pyoderma; Rate; Reaction; Research; Research Infrastructure; Research Personnel; Rheumatic Fever; Rheumatic Heart Disease; Role; Route; Safety; School-Age Population; Series; Serological; Serum; Site; Skin; Streptococcal Infections; Streptococcal Vaccines; Streptococcus pyogenes; Surface; Surveys; T-Lymphocyte; Testing; Toll-like receptors; Toxicology; Toxoids; Transgenic Mice; Vaccination; Vaccine Clinical Trial; Vaccines; Variant; Work; aluminum sulfate; analytical method; base; cohort; cross reactivity; falls; field study; human tissue; immunogenicity; in vivo; interest; lymph nodes; method development; mortality; multicatalytic endopeptidase complex; multiple myeloma M Protein; mutant; pathogen; pre-clinical; preclinical study; prevent; programs; prospective; respiratory; scale up; size; vaccine development; volunteer

Streptococcus pyogenes which is also known as group A streptococcus (GAS) is a Gram positive bacterial pathogen that is responsible for numerous diseases including relatively benign pharyngitis and skin infections to serious invasive diseases including necrotizing fasciitis and the post-infectious sequelae rheumatic fever, rheumatic heart disease and glomerulonephritis. Presently, there is no strategy for primary prevention that is proven to work in less-developed countries, so a vaccine is clearly needed. Some vaccine strategies under development may not be effective in less developed countries. Our long-term goal is the development of broad-spectrum global vaccine that prevents GAS infection and its associated diseases, including rheumatic fever. Our GAS vaccine candidate is based on a peptide antigen from the conserved region of the M-protein We have four potential vaccine constructs that use this antigen, each of which has shown good immunogenicity, safety and protection in pre-clinical studies. There are three overall objectives for the work in the current proposal: (1) Progression of the most advanced of our construct to clinical trials. At the conclusion of this work, we expect to have completed: (a) An initial phase I trial in adult volunteers in Australia. (b) A larger multicentre phase I trial in adult volunteers in Australia and adult volunteers in a developing country. (e) A small phase I trial in child volunteers in a developing country. (2) Further development of the conserved region peptide as an intranasal vaccine. (3) Field studies in a developing country to establish correlates of protection that may be used in phase II and III clinical trials of the conserved region peptide, and to establish a field site for these later-phase trials.

化脓性链球菌也被称为A群链球菌（GAS），是一种革兰氏阳性细菌

项目成果

High prevalence of rheumatic heart disease by clinical and echocardiographic screening among children in Fiji.

通过临床和超声心动图筛查，斐济儿童中风湿性心脏病的患病率很高。

• 发表时间: 2009
• 期刊: The Journal of heart valve disease
• 作者: Steer,AndrewC;Kado,Joseph;Wilson,Nigel;Tuiketei,Timaima;Batzloff,Michael;Waqatakirewa,Lepani;Mulholland,EKim;Carapetis,JonathanR
• 通讯作者: Carapetis,JonathanR

Long-term antibody memory induced by synthetic peptide vaccination is protective against Streptococcus pyogenes infection and is independent of memory T cell help.

• DOI: 10.4049/jimmunol.1202333
• 发表时间: 2013-03-15
• 期刊: Journal of immunology (Baltimore, Md. : 1950)
• 作者: Pandey M;Wykes MN;Hartas J;Good MF;Batzloff MR
• 通讯作者: Batzloff MR

Prospective surveillance of invasive group a streptococcal disease, Fiji, 2005-2007.

• DOI: 10.3201/eid1502.080558
• 发表时间: 2009-02
• 期刊: Emerging infectious diseases
• 影响因子: 11.8
• 作者: Steer AC;Jenney A;Kado J;Good MF;Batzloff M;Waqatakirewa L;Mullholland EK;Carapetis JR
• 通讯作者: Carapetis JR

emm and C-repeat region molecular typing of beta-hemolytic Streptococci in a tropical country: implications for vaccine development.

热带国家 β 溶血性链球菌的 emm 和 C 重复区域分子分型：对疫苗开发的影响。

• DOI: 10.1128/jcm.00312-09
• 发表时间: 2009
• 期刊: Journal of clinical microbiology
• 影响因子: 9.4
• 作者: Steer,AndrewC;Magor,Graham;Jenney,AdamWJ;Kado,Joseph;Good,MichaelF;McMillan,David;Batzloff,Michael;Carapetis,JonathanR
• 通讯作者: Carapetis,JonathanR